Novo flunks kidney disease trial, again linking obesity prospect to neuropsychiatric side effects

[cafead]

via Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that left investors underwhelmed, the Danish drugmaker has reported the failure of a midphase diabetic kidney disease trial of the molecule.

article source